1.Kelly, CP, Pothoulakis, C, LaMont, JT. Clostridium difficile colitis. N Engl J Med 1994;330:257–262.
2.McFarland, LV. Epidemiology of infectious and iatrogenic nosocomial diarrhea in a cohort of general medicine patients. Am J Infect Control 1995;23:295–305.
3.Kyne, L, Hamel, MB, Polavaram, R, Kelly, CP. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis 2002;34:346–353.
4.Centers for Disease Control and Prevention. Recommendations for preventing the spread of vancomycin resistance: recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). Am J Infect Control 1995;23:87–94.
5.McFarland, LV, Surawicz, CM, Rubin, M, Fekety, R, Elmer, GW, Greenberg, RN. Recurrent Clostridium difficile disease: epidemiology and clinical characteristics. Infect Control Hosp Epidemiol 1999;20(1):43–50.
6.Kyne, L, Kelly, CP. Recurrent Clostridium difficile diarrhoea. Gut 2001;49:152–153.
7.Spencer, RC. The role of antimicrobial agents in the aetiology of Clostridium difficile-associated disease. J Antimicrob Chemother 1998; 41(suppl C):21–27.
8.Brown, E, Talbot, GH, Axelrod, P, Provencher, M, Hoegg, C. Risk factors for Clostridium difficile toxin-associated diarrhea. Infect Control Hosp Epidemiol 1990;11:283–290.
9.Bliss, DZ, Johnson, S, Savik, K, Clabots, CR, Willard, K, Gerding, DN. Acquisition of Clostridium difficile and Clostridium difficile-associated diarrhea in hospitalized patients receiving tube feeding. Ann Intern Med 1998;129:1012–1019.
10.Bignardi, GE. Risk factors for Clostridium difficile infection. J Hosp Infect 1998;40:1–15.
11.McFarland, LV, Surawicz, CM, Stamm, WE. Risk factors for Clostridium difficile carriage and C. dificile-associated diarrhea in a cohort of hospitalized patients. J Infect Dis 1990;162:678–684.
12.Horn, SD. Measuring severity of illness: comparisons across institutions. Am J Public Health 1983;73:25–31.
13.Horn, SD, Sharkey, PD, Bertram, DA. Measuring severity of illness: homogeneous case mix groups. Med Care 1983;21:14–30.
14.Horn, SD, Chachich, B, Clopton, C. Measuring severity of illness: a reliability study. Med Care 1983;21:705–714.
15.Owens, WD, Felts, JA, Spitznage, EL Jr. ASA physical status classifications: a study of consistency of ratings. Anesthesiology 1978;49:239–243.
16.Kyne, L, Warny, M, Qamar, A, Kelly, CP. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med 2000;342:390–397.
17.Killip, T 3rd, Kimball, JT. Treatment of myocardial infarction in a coronary care unit: a two year experience with 250 patients. Am J Cardiol 1967;20:457–464.
18.Charlson, ME, Sax, FL, MacKenzie, CR, Fields, SD, Braham, RL, Douglas, RG Jr. Assessing illness severity: does clinical judgment work? J Chronic Dis 1986;39:439–452.
19.Charlson, ME, Pompei, P, Ales, KL, MacKenzie, CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373–383.
20.McFarland, LV, Mulligan, ME, Kwok, RY, Stamm, WE. Nosocomial acquisition of Clostridium difficile infection. N Engl J Med 1989;320:204–210.
21.Hanley, JA, McNeil, BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982;143:29–36.
22.Metz, CE. Basic principles of ROC analysis. Semin Nucl Med 1978;8:283–298.
23.Katz, DA, Lynch, ME, Littenberg, B. Clinical prediction rules to optimize cytotoxin testing for Clostridium difficile in hospitalized patients with diarrhea. Am J Med 1996;100:487–495.
24.Katz, DABates, DW, Rittenberg, E, et al. Predicting Clostridium difficile stool cytotoxin results in hospitalized patients with diarrhea. J Gen Intern Med 1997;12:57–62.
25.Nelson, DE, Auerbach, SB, Baltch, AL, et al. Epidemic Clostridium difficile-associated diarrhea: role of second- and third-generation cephalosporins. Infect Control Hosp Epidemiol 1994;15:88–94.
26.Tacconelli, E, Mazzella, P, Tumbarello, M. Clostridium difficile associated diarrhea: two years of observation in a University Hospital. L'Igiene Moderna 1994;102:95–104.
27.Wilcox, MH. Cleaning up Clostridium difficile infection. Lancet 1996; 348:767–768.
28.Samore, MH. Epidemiology of nosocomial Clostridium difficile diarrhoea. J Hosp Infect 1999;43(suppl):S183–S190.
29.Kyne, L, Farrell, RJ, Kelly, CP. Clostridium difficile. Gastroenterol Clin North Am 2001;30:753–777.
30.Worsley, MA. Infection control and prevention of Clostridium difficile infection. J Antimicrob Chemother 1998;41 (suppl C):59–66.
31.Pear, SM, Williamson, TH, Bettin, KM, Gerding, DN, Galgiani, JN. Decrease in nosocomial Clostridium difficile-associated diarrhea by restricting clindamycin use. Ann Intern Med 1994;120:272–277.
32.Climo, MW, Israel, DS, Wong, ES, Williams, D, Coudron, P, Markowitz, SM. Hospital-wide restriction of clindamycin: effect on the incidence of Clostridium difficile-associated diarrhea and cost. Ann Intern Med 1998; 128(12 Part 1):989–995.
33.McNulty, C, Logan, M, Donald, IP, et al. Successful control of Clostridium difficile infection in an elderly care unit through use of a restrictive antibiotic policy. J Antimicrob Chemother 1997;40:707–711.
34.Surawicz, CM, Elmer, GW, Speelman, P, McFarland, LV, Chinn, J, van Belle, G. Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii: a prospective study. Gastroenterology 1989;96:981–988.
35.Gorbach, SL, Chang, TW, Goldin, B. Successful treatment of relapsing Clostridium difficile colitis with Lactobacillus GG. Lancet 1987;2:1519.
36.McFarland, LV, Surawicz, CM, Greenberg, RN, et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 1994;271:1913–1918.
37.Surawicz, CM, McFarland, LV, Greenberg, RN, et al. The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis 2000;31:1012–1017.
38.Heerze, LD, Keim, MA, Talbot, JA, Armstrong, GD. Oligosaccharide sequences attached to an inert support (SYNSORB) as potential therapy for antibiotic-associated diarrhea and pseudomembranous colitis. J Infect Dis 1994;169:1291–1296.
39.Castagliuolo, I, LaMont, JT, Qiu, B, Nikulasson, ST, Pothoulakis, C. A receptor decoy inhibits the enterotoxic effects of Clostridium difficile toxin A in rat ileum. Gastroenterology 1996;111:433–438.
40.Kyne, L, Kelly, C. Prospects for a vaccine for Clostridium difficile. BioDrugs 1998;10:173–181.